[
  {
    "ts": null,
    "headline": "VIG May Be Poised To Outperform FDVV In 2026",
    "summary": "Compare VIG vs. FDVV ETF performance and explore why Vanguard Dividend Appreciation Index Fund ETF Shares' (VIG) sector focus means 2026 upside.",
    "url": "https://finnhub.io/api/news?id=738e6ba07f0dbdd8905da82974a7cce56d62259f98ce3a74ceff2811f8920e9f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767136961,
      "headline": "VIG May Be Poised To Outperform FDVV In 2026",
      "id": 137945783,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2244450943/image_2244450943.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Compare VIG vs. FDVV ETF performance and explore why Vanguard Dividend Appreciation Index Fund ETF Shares' (VIG) sector focus means 2026 upside.",
      "url": "https://finnhub.io/api/news?id=738e6ba07f0dbdd8905da82974a7cce56d62259f98ce3a74ceff2811f8920e9f"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Ends Mid-Stage Eczema Study After Missing Efficacy Bar",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with moderate to severe atopic dermatitis. The decision followed an interim analysis showing the treatment did not meet its […]",
    "url": "https://finnhub.io/api/news?id=d46250ec6f6c2bc5987107df396cf78929ec23506bc1e3827c85a4683da2e592",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767136168,
      "headline": "Johnson & Johnson (JNJ) Ends Mid-Stage Eczema Study After Missing Efficacy Bar",
      "id": 137950179,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with moderate to severe atopic dermatitis. The decision followed an interim analysis showing the treatment did not meet its […]",
      "url": "https://finnhub.io/api/news?id=d46250ec6f6c2bc5987107df396cf78929ec23506bc1e3827c85a4683da2e592"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Tweedy Browne Portfolio - Q3 2025 Update",
    "summary": "Read here for Tweedy Browne's latest 13F updates, top holdings like Ionis Pharma, and shifting investment strategies.",
    "url": "https://finnhub.io/api/news?id=f534de22c8b9f9812ab099225a3acf0a9cdfe2449a721143ff270eb7ffa1312d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767132693,
      "headline": "Tracking Tweedy Browne Portfolio - Q3 2025 Update",
      "id": 137945592,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160013511/image_1160013511.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Read here for Tweedy Browne's latest 13F updates, top holdings like Ionis Pharma, and shifting investment strategies.",
      "url": "https://finnhub.io/api/news?id=f534de22c8b9f9812ab099225a3acf0a9cdfe2449a721143ff270eb7ffa1312d"
    }
  },
  {
    "ts": null,
    "headline": "Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever",
    "summary": "Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income.",
    "url": "https://finnhub.io/api/news?id=f47296a46b61bef010599896d15e6917727acebf41489a92390b84fd55918211",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767105300,
      "headline": "Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever",
      "id": 137940275,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income.",
      "url": "https://finnhub.io/api/news?id=f47296a46b61bef010599896d15e6917727acebf41489a92390b84fd55918211"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains",
    "summary": "Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.",
    "url": "https://finnhub.io/api/news?id=52fbed3b5a0e5ecc7e3763f336b68aeb43f346ee25b9db555a7d359898e73d26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767099540,
      "headline": "3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains",
      "id": 137940276,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.",
      "url": "https://finnhub.io/api/news?id=52fbed3b5a0e5ecc7e3763f336b68aeb43f346ee25b9db555a7d359898e73d26"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights International Business Machines, Analog Devices, Johnson & Johnson's, The Gap and Hewlett Packard Enterprise",
    "summary": "IBM leads a list of high-yield S&P 500 picks for 2026 as steady cash flow, dividends and AI exposure appeal amid market volatility.",
    "url": "https://finnhub.io/api/news?id=ce1e8061572f14428497460e463a9b16fc706c35722194a4c8857825f77e9602",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767093240,
      "headline": "The Zacks Analyst Blog Highlights International Business Machines, Analog Devices, Johnson & Johnson's, The Gap and Hewlett Packard Enterprise",
      "id": 137940277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "IBM leads a list of high-yield S&P 500 picks for 2026 as steady cash flow, dividends and AI exposure appeal amid market volatility.",
      "url": "https://finnhub.io/api/news?id=ce1e8061572f14428497460e463a9b16fc706c35722194a4c8857825f77e9602"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson acquires Halda Therapeutics for $3.05bn",
    "summary": "The deal adds early-stage candidates for breast, lung, and other tumour types, using RIPTAC technology, to J&J’s pipeline.",
    "url": "https://finnhub.io/api/news?id=41df669284083f143ec2fe755a2d6d20be5b98f1e0ae47ff9e0a368224399db2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767091917,
      "headline": "Johnson & Johnson acquires Halda Therapeutics for $3.05bn",
      "id": 137940278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The deal adds early-stage candidates for breast, lung, and other tumour types, using RIPTAC technology, to J&J’s pipeline.",
      "url": "https://finnhub.io/api/news?id=41df669284083f143ec2fe755a2d6d20be5b98f1e0ae47ff9e0a368224399db2"
    }
  }
]